Efficacy of gonadotropin-releasing hormone antagonists in the management of patients with severe early-onset ovarian hyperstimulation syndrome

Le résumé fourni par la source

Objective. To study the efficacy of gonadotropin-releasing hormone (GnRH) antagonists in the treatment of patients with severe early-onset ovarian hyperstimulation syndrome (OHSS). Patients and methods. This study including 60 women was conducted between January 2021 and January 2023 at Al-Azhar University Maternity Hospitals and private ART centers. Approval from the Research Ethics Committee was obtained to conduct the study. Patients were randomly divided into two groups: group I (n = 30; control group) received only standard therapy for severe OHSS, group II (n = 30; study group) received standard therapy and cetrorelix. Results. The percentage of patients who required paracentesis, the mean serum creatinine level 48 hours after GnRH antagonist injection, and the percentage of patients who had persistent oliguria 48 hours after GnRH antagonist injection were significantly lower in the study group (cetrorelix group) compared with the control group. Patients in the cetrorelix group had a significantly shorter mean length of hospital stay and mean recovery time than patients in the control group. Conclusion. The therapeutic efficacy of the GnRH antagonist cetrorelix for the treatment of patients with severe early-onset OHSS was demonstrated. Key words: gonadotropin releasing-hormone antagonist; severe early-onset ovarian hyperstimulation syndrome

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.